RESEARCH
All products are supplied strictly for laboratory and research use only — not for human or veterinary use. By entering, you confirm you are 18 or older and agree to our Terms & Conditions.
Under 18? Leave this siteResearch Information
Metabolic · Triple receptor agonist peptide
Short research overview
Retatrutide is classified as a triple receptor agonist peptide because its research profile spans GLP-1, GIP and glucagon receptors. This multi-receptor classification separates it from entries organised around one receptor family or a non-receptor peptide pathway.
View the Retatrutide product pageHow it is being studied
Research attention is directed to combined agonism across the three named receptor systems and their associated metabolic signalling. The relevant question is the interaction of those signalling pathways, not attribution to only one incretin or glucagon receptor.
Areas of Research
Current Research Status
Research reference only. This entry does not represent an approved therapeutic use or medical recommendation.
Available Strength
10mg · 20mg · 30mg
Scientific References
Retatrutide literature index
PubMed · National Library of Medicine
Retatrutide 10mg analytical certificate
PEPY verification archive
Retatrutide 20mg analytical certificate
PEPY verification archive
Retatrutide 30mg analytical certificate
PEPY verification archive
Research literature
Cell Metabolism, 2022
This primary discovery study examined receptor activity in vitro, metabolic endpoints in mouse models and first-in-human single-ascending-dose observations. The findings established an early experimental basis for further clinical investigation.
View PubMed recordThe Lancet, 2022
This early-phase trial investigated safety, tolerability, pharmacokinetics and pharmacodynamic endpoints in adults with type 2 diabetes. Its limited duration and phase 1b design mean the observations were exploratory.
View PubMed recordThe New England Journal of Medicine, 2023
This randomised phase 2 study evaluated dose-response, safety and body-weight endpoints over 48 weeks in adults with obesity or overweight with a related condition. Retatrutide remained an investigational compound and the study was not designed to establish approved use.
View PubMed recordThe Lancet, 2023
This phase 2 trial investigated glycaemic, body-weight and safety endpoints in adults with type 2 diabetes. The results apply to the study population, comparators and predefined trial conditions rather than broader settings.
View PubMed recordNature Medicine, 2024
This phase 2a substudy examined liver-fat and related metabolic measurements in a subset of participants with metabolic dysfunction-associated steatotic liver disease. The sample and substudy design require the findings to be interpreted within their specific experimental context.
View PubMed recordPublished studies may involve different populations, study designs, experimental conditions and endpoints. References are provided for research context only and do not establish approved or therapeutic use.
For Research Purposes Only
This information is provided as a scientific reference and does not include medical, dosing, administration or human-use guidance.
Your cart is empty.